In Q3 2026 IOVA rose 256% making it one of the best mid cap performing stock in the U.S. Sept 29 it jumped 31.5% they also increased there expected revenue from 350-370m to 410-420m. The main driver Amtagvi and proluekin, it's cancer treatments. Q2 product revenue reached a record 99.3m as of Oct 5 it's $14.15 the really big opurtunity is them spreading beyond melanoma, they are in a phase 3 melanoma trial right now. But since it's already grown so much this year it's definitely not a safe buy but high risk high reward.